---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-26-000067"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2026-08-10T20:22:45+00:00"
generated_at: "2026-08-10T20:24:08.070714+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biohaven Q2 net loss narrows to $137.3M; advances Graves, epilepsy, oncology pipeline

## Summary
- Net loss $137.3M ($0.91/share) vs $198.1M ($1.94/share) in Q2 2025; non-GAAP loss $118.1M ($0.78/share).
- Cash, equivalents, marketable securities and restricted cash totaled ~$270.5M as of June 30, 2026.
- BHV-1300 Phase 3 in Graves' initiated; Phase 1b showed >80% mean reduction of pathogenic TSHR-IgG1 by week 12.
- Opakalim RISE3 topline expected 2H 2026; IGE study showed median time to second seizure 141 vs 47 days placebo.
- New clinical supply agreement with Regeneron to evaluate BHV-1530 ADC in combination with Libtayo.

## SEC filing metadata
- accession: 0001935979-26-000067
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2026-08-10T20:22:45+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/0001935979-26-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/bhvn-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-26-000067
- JSON: https://secwatch.observer/filing/0001935979-26-000067.json
- Plain text: https://secwatch.observer/filing/0001935979-26-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.